Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Conditions

Melanoma 34 Neoplasms 21 Carcinoma, Non-Small-Cell Lung 7 Brain Neoplasms 5 Skin Neoplasms 4 Neoplasm Metastasis 4 Glioma 4 Thyroid Carcinoma, Anaplastic 2 Parkinson Disease 4, Autosomal Dominant Lewy Body 2 Oligodendroglioma 2 Neurofibroma, Plexiform 2 Neurocytoma 2 Neuroblastoma 2 Lung Neoplasms 2 Histiocytosis, Langerhans-Cell 2 Glioblastoma 2 Ganglioneuroma 2 Ganglioglioma 2 Colorectal Neoplasms 2 Astrocytoma 2 Small Cell Lung Carcinoma 1 Recurrence 1 Rectal Neoplasms 1 Nonseminomatous germ cell tumor 1 Neurofibromatosis 1 1 Multiple Myeloma 1 Melanoma, Cutaneous Malignant 1 Leukemia, Hairy Cell 1 Gastrointestinal Stromal Tumors 1 Fever 1

Interventions

Dexamethasone 64 Lenalidomide 34 pomalidomide 33 Cyclophosphamide 33 Rituximab 31 Bortezomib 29 venetoclax 27 fludarabine 26 Gemcitabine 21 carfilzomib 20 Paclitaxel 19 pembrolizumab 17 daratumumab 16 Cisplatin 16 Carboplatin 15 Calcium Dobesilate 14 Azacitidine 14 ibrutinib 12 Docetaxel 12 Cytarabine 12 obinutuzumab 11 Nivolumab 11 durvalumab 10 Doxorubicin 10 Bevacizumab 10 selinexor 9 cemiplimab 9 blinatumomab 9 Injections 9 Cetuximab 9

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Recurrence × dabrafenib × Clear all

NCT06262919 2025-12-30

Special Drug Use-results Surveillance of Tafinlar/Mekinist

Novartis

Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡